Board of Directors
Roy Whitfield
Executive Chairman
Former Chairman and CEO, Incyte Corporation
Robert Al Beardsley, Ph.D.
SImile Investor LLC
Managing Member
Eugene Butcher, M.D.
BioSeek founder
Professor of Pathology, Stanford University
Lionel Carnot
Bay City Capital
Investment Partner
W. Michael Gallatin, Ph.D.
Former VP Research, ICOS Pharmaceuticals
Peter Staple
Former Chief Executive Officer
Michael C. Venuti, Ph.D.
Chief Executive Officer
Blake Winchell
Fremont Ventures
Managing General Partner
Roy Whitfield, Executive Chairman
Roy Whitfield has over 20 years of management and governance experience in the biotechnology industry. Most recently, Roy served as CEO and Chairman of Incyte Corporation, a genomics company he co-founded in 1991. Incyte pioneered the commercialization of high throughput and information technology in pharmaceutical and medical research. At Incyte, Roy executed the first genomics initial public offering (IPO) and later raised over $700 million in financing. He received the 1997 Northern California Entrepreneur of the Year Award for Life Sciences and the 1996 Best of Biotech Award for Most Creative and Significant Strategic Alliances. Roy also serves on the board of directors of Incyte Corporation, Nektar Therapeutics and several private companies, and in the past served on the boards of Aurora Biosciences and the Biotechnology Industry Organization (BIO).
Top of page
Al Beardsley, Ph.D.
Al Beardsley, Ph.D., is currently a private investor and Managing Member of SImile Investors LLC, and serves as CEO of Kereos, Inc. Before joining Kereos,
Al was with bioStrategies Group, Inc. - a leading strategic consulting group for the biotech and life science sectors - as Principal - Business Development Practice. Prior to that he was in equity research at Vector Securities International, Inc., helped found several companies, and served as CEO of Enzyme Organics, Inc. Al received his Ph.D. in biochemical engineering from the University of Iowa and his MBA in Finance from the University of Chicago.
Top of page
Eugene Butcher, M.D.
Eugene C. Butcher, M.D., BioSeek co-founder and Chair of the Scientific Advisory Board. Dr. Butcher is a Professor in the Department of Pathology at Stanford
University, and a staff physician at the Veterans Affairs Palo Alto Health Care System. He received a B.S. in Chemistry from the Massachusetts Institute of Technology and an M.D. from the Washington University School of Medicine, St. Louis, MO. His work has focused on the cellular and molecular mechanisms of leukocyte trafficking in immunity and inflammation, and on systems level insights into mechanisms of cell-cell recognition and function. He has been elected to the American Association of Physicians, and has been awarded the Warner Lambert/Parke Davis Award by the American Association of Pathologists, the AAI-Huang Foundation Meritorious Career Award by the American Association of Immunologists, and an Outstanding Inventor Award from Stanford University. He received the Crafoord Prize from the Swedish Academy of Sciences in 2004 for the scientific discovery of mechanisms of leukocyte trafficking contributing
to the treatment of arthritis and inflammatory diseases. He is the author of 300 scientific articles and an inventor on nine US patents. Dr. Butcher was Scientific Co-Founder and Co-Chair of the Scientific Advisory Board of Leukosite, Inc. (now merged with Millennium Pharmaceuticals) and has served on the Scientific Advisory Boards of Millennium, Medimmune, and Thios Pharmaceuticals.
Top of page
Lionel Carnot
Lionel Carnot is an Investment Partner at Bay City Capital and has been extensively involved in the firm's activities since he joined The Pritzker Organization in 2000. Prior to The Pritzker Organization, Mr. Carnot was a Principal at Oracle Partners, a healthcare hedge fund. He also held several positions in the pharmaceutical industry, including Product Manager for Prozac at Eli Lilly, as well as several sales and marketing positions at Aventis. Mr. Carnot was also a strategy and management consultant to the biopharmaceutical industry while at Booz Allen & Hamilton and Accenture Strategic Services. Mr. Carnot is a member of the Boards of Directors of Bioseek and Pathway Diagnostics, and serves as an observer on the boards of Reliant Pharmaceuticals and Via Pharmaceuticals. Mr. Carnot holds an M.B.A. with Distinction from INSEAD and an M.S. with Honors in Molecular Biology from the University of Geneva.
Top of page
Michael Gallatin, Ph.D.
W. Michael Gallatin is the former Vice President and Scientific Director of ICOS Corporation. He joined ICOS in 1990 as Director of the Cell Adhesion Program and became a Senior Director, Science, in 1992. He was appointed Vice President, Biological Research in 1993. Prior to joining ICOS, Dr. Gallatin was a faculty member of the Fred Hutchinson Cancer Research Center in Seattle, and an affiliate faculty member of the Department of Microbiology at the University of Washington. He has been actively engaged in research relating to immunobiology and cell adhesion for over 20 years. He received his Ph.D. in immunology from the University of Alberta (Canada) and was a postdoctoral fellow at Stanford University.
Top of page
Peter D. Staple
Peter D. Staple was BioSeek's Chief Executive Officer from 2002 through November, 2007. Mr. Staple has more than 20 years experience in the biotech and pharmaceutical industries. Prior to joining BioSeek, he was a member of the senior executive team at ALZA Corporation, where he was most recently Executive Vice President, Chief Administrative Officer and General Counsel. He played a central role in the partnering transactions, financings and acquisitions that enabled rapid growth in ALZA's business, and in ALZA's merger with Johnson & Johnson. Mr. Staple joined ALZA after extensive experience in senior positions in the biotechnology industry at Cetus and Chiron Corporations, where his responsibilities covered corporate partnering, licensing, mergers and acquisitions, and financing transactions, including transactions involving commercialization of PCR, branch DNA, hepatitis C and HIV screening technologies, and therapeutic products including Proleukin and Betaseron. Prior to entering the biotechnology industry, Mr. Staple practiced corporate and securities law at Heller Ehrman White & McAuliffe in San Francisco. Mr. Staple serves on the board of directors of DepoMed, Inc., and on the Board of Visitors at Stanford Law School. He holds B.A. and J.D. degrees from Stanford University.
Top of page
Michael C. Venuti, Ph.D., Chief Executive Officer
Michael C. Venuti, Ph.D., joined BioSeek as its Chief Executive Officer and member of the Board of Directors in November, 2007. Dr. Venuti has over 25 years experience in the biotech and pharmaceutical industries. He previously served as Chief Executive Officer of Discovery Partners International, a small molecule-based drug discovery services company. Since the Discovery Partners merger with Infinity Pharmaceuticals in September, 2006, Dr. Venuti had served as a consultant to TPG Growth Biotech Ventures, as well as to a number of biotech companies. Before becoming CEO of Discovery Partners, Dr. Venuti served as Chief Scientific Officer, and had been a member of its board of directors before becoming CSO. Prior to joining Discovery Partners, he served as General Manager of Celera Genomics Group's South San Francisco site after its acquisition of Axys Pharmaceuticals, Inc. He served as Senior Vice President, Research and Preclinical Development, of Axys Pharmaceuticals prior to its acquisition by Celera. In this capacity, he was responsible for all small molecule target identification, medicinal chemistry, drug discovery and preclinical development activities. Prior to joining Axys, Dr. Venuti was Director of Bioorganic Chemistry at Genentech, Inc., and had begun his research career in medicinal chemistry at Syntex.
Dr. Venuti holds an A.B. from Dartmouth College, a Ph.D. in organic chemistry from the Massachusetts Institute of Technology, and completed postdoctoral training in the Institute of Organic Chemistry at Syntex Research. He is on the board of directors of Infinity Pharmaceuticals, and serves as Executive Scientific Advisor to BIO Ventures for Global Health, a non-profit advocacy group focused on drug discovery and development for neglected diseases. Dr. Venuti holds an appointment as Adjunct Professor of Chemistry in the Department of Pharmaceutical Chemistry at the University of California, San Francisco.
Top of page
Blake Winchell
Blake Winchell is the Managing General Partner of Fremont Ventures, and a Managing Director of the Fremont Group, a San Francisco-based private investment company with approximately $6 billion in assets under management across a broad array of assets classes. Prior to Fremont Ventures, Blake was an investment professional with Generation Ventures and Leucadia National Corporation, as well as a manager in the international consulting firm, Bain and Company. Blake graduated as a Choate Scholar from Dartmouth College and holds an MBA from the Stanford University Graduate School of Business. He is a Certified Public Accountant. In addition to BioSeek, Blake sits on the boards of directors of GlobalServe, Inc. He also serves on the International Advisory Board of the Instituto de Empressa in Madrid and on the Executive Committee of the Skyline Council of the Boy Scouts of America. He is a member of the World President's Organization.
Top of page
|
